08:57 AM EDT, 03/14/2025 (MT Newswires) -- Palisade Bio ( PALI ) said Friday it began dosing ulcerative colitis patients in the final cohort of its phase 1a/b study of PALI-2108.

The company said it had completed five single ascending dose cohorts and three of four multiple ascending dose cohorts, with no serious adverse events or treatment-related adverse events tied to lab results or EKGs.

Palisade Bio ( PALI ) said it plans to report topline data in H1.

Shares of the company were up 3% in recent Friday premarket activity.